Cargando…
Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go?
With an increased understanding of the tumor biology of squamous cell carcinoma of the head and neck (SCCHN), targeted therapies have found their way into the clinical treatment routines against this entity. Nevertheless, to date platinum-based cytostatic agents remain the first line choice and targ...
Autores principales: | von der Grün, Jens, Rödel, Franz, Brandts, Christian, Fokas, Emmanouil, Guckenberger, Matthias, Rödel, Claus, Balermpas, Panagiotis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521064/ https://www.ncbi.nlm.nih.gov/pubmed/30987257 http://dx.doi.org/10.3390/cancers11040472 |
Ejemplares similares
-
C-Reactive Protein-to-Albumin Ratio as Prognostic Marker for Anal Squamous Cell Carcinoma Treated With Chemoradiotherapy
por: Martin, Daniel, et al.
Publicado: (2019) -
Peripheral Leukocytosis Is Inversely Correlated with Intratumoral CD8+ T-Cell Infiltration and Associated with Worse Outcome after Chemoradiotherapy in Anal Cancer
por: Martin, Daniel, et al.
Publicado: (2017) -
Ultrafast Spectroscopy of Photoactive Molecular Systems from First Principles:
Where We Stand Today and Where We Are Going
por: Conti, Irene, et al.
Publicado: (2020) -
Psychopharmacology Today: Where are We and Where Do We Go From Here?
por: Schwartz, Thomas L.
Publicado: (2010) -
The Role of Angiogenesis in Haemophilic Arthropathy: Where Do We Stand and Where Are We Going?
por: Agapidou, Alexandra, et al.
Publicado: (2016)